Gilead Sciences Reports Softer Sovaldi Revenues By: Benzinga via Benzinga October 28, 2014 at 17:15 PM EDT Gilead Sciences, Inc. (NASDAQ: GILD) reported significantly softer sales of its blockbuster Hep C drug, Sovaldi. Gilead ... Read More >> Related Stocks: Gilead Sciences